ECE2015 Guided Posters Diabetes and obesity–Clinical obesity and cardiovascular (8 abstracts)
Lviv National Medical University, Lviv, Ukraine.
Introduction: The aim of study was to analyse the effect of long-chain polyunsaturated higher ω-3 fatty acids (PUFAs) on the arterial stiffness parameters in patients with type 2 diabetes (T2DM) and cardiovascular autonomic neuropathy (CAN).
Description of methods: The study involved 39 patients with moderate CAN (55.2±3.8 years, HbA1c 7.1±0.5%. The aorta (AIxao), brachial augmentation index (AIxbr), pulse wave velocity (PWV) were assessed by TensioMedTM Arteriograph 24 (Hungary). Patients with CAN were allocated to two groups: control (n=18) received standart therapy and treatment (n=21) received in addition one capsule/day of the ω-3 PUFAs (Δ90%). The duration of the study was 3 months. Statistics: ANOVA.
Results: The arterial stiffness parameters in patients with moderate CAN exceed the physiological values, in particular AIxao +26.2% (P<0.01), AIxbr +66.2% (P<0.001), PWV +24.7% (P<0.001) compared to patients with T2DM without CAN. Prescription of ω-3 PUFA was accompanied by more decrease of AIxao, PWV during the 24 h, decrease of AIxao, PWV during the day and decrease of AIxao, AIxbr, PWV during the night. Simultaneously no significant influence on the AIxbr during the active period of day was not found (table).
Patients with T2DM and CAN (n=39) | |||||
Parameters | Groups | Day/night | Baseline | After treatment | % change from baseline |
AIxao, % | Control | Day | 30.4±1.97 | 28.4±1.68 | −4.3±4.76 |
Night | 33.2±1.98 | 30.1±1.27 | −6.6±4.15 | ||
Treatment | Day | 32.0±1.32 | 26 4±1.12b | −16.2±3.12 | |
Night | 36.6±1.65 | 31.7±1.23a | −11.2±4.2 | ||
AIxbr, % | Control | Day | −10.6±3.37 | −12.0±3.11 | −19.3±12.14 |
Night | −4.2±2.8 | −5.9±2.48 | −10.0±17.23 | ||
Treatment | Day | −9.8±2.76 | −14.3±2.84 | −42.8±9.0 | |
Night | −1.6±2.79 | −10.4±3.23a | −98.0±18.1 | ||
PWV, m/s | Control | Day | 10.2±0.4 | 9.6±0.4 | −6.0±2.21 |
Night | 10.9±0.4 | 10.3±0.36 | −4.93±1.41 | ||
Treatment | Day | 11.0±0.35 | 9.7±0.39a | −11.6±2.09 | |
Night | 11.3±0.48 | 9.0±0.44b | −18.9±3.9 | ||
Note: The results are given as absolute values and as % change from baseline, (Δ%, Mean±SEM); aP<0.05, bP<0.01 compared to baseline. |
Conclusion: Therefore, the administration of ω-3 PUFA for 3 month promotes reduction of artery stiffness parameters in patients with T2DM and CAN.